Mr. Speaker, there was a report tabled just last week from an advisory group on this whole question. That report has been received by Health Canada officials and technical people and is being examined very carefully.
I should tell the member in response to his question more broadly that we have a world class surveillance system at Health Canada in relation to contaminants, including CJD. CJD is the subject of an extensive research project that has been started at Health Canada so that we can better understand this new class of prion contaminants in blood. I assure the House we take the risk very seriously.